SpyGlass Pharma, Inc. is a late-stage biopharmaceutical, which engages in the development of treatment paradigm for patients living with chronic eye conditions.
$32.24-1.95%
报价 2026-11-16
市值
$1.08B
EV
$515.6M
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -16.0%
$17.56$38.37
筛选结果
pipeline · 2026-11-16Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
爆发潜力
2026-11-16不在筛选范围:industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告(约 1–3 分钟),结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
同行业市值相近 · Biotechnology| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| SGPSpyGlass Pharma, Inc. Common Stock | $1.08B | -1.9% | – | 0% | – | – | – | |
| KARDKardigan, Inc. | $1.15B | -7.0% | – | 0% | – | – | – | |
| INBXInhibrx Biosciences, Inc. | $1.14B | -6.8% | -46.2% | 0% | – | – | – | |
| DRTSAlpha Tau Medical Ltd. | $1.11B | -10.5% | – | 0% | – | – | – | |
| ANROAlto Neuroscience, Inc. | $1.09B | -8.2% | – | 0% | – | – | – | |
| GPCRStructure Therapeutics Inc. | $1.07B | -7.2% | – | 0% | – | – | – | |
| NKTRNektar Therapeutics | $1.05B | -2.2% | -6.0% | 99.4% | – | – | – | |
| VORVor Biopharma Inc. | $1.03B | -2.3% | +110.0% | 0% | – | 2.3x | – | |
| SPTXSeaport Therapeutics, Inc. Common Stock | $1.02B | -4.3% | – | 0% | – | – | – | |
| 同行中位数 | – | – | -6.0% | 0% | – | 2.3x | – |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据(首次研究运行后填充)。